Novel CB1 receptor antagonist BAR-1 modifies pancreatic islet function and clinical parameters in prediabetic and diabetic mice

BACKGROUDS: Cannabinoid receptor antagonists have been suggested as a novel treatment for obesity and diabetes. We have developed a synthetic cannabinoid receptor antagonist denominated BAR-1. As the function and integrity of a β-cell cellular structure are important keys for diabetes onset, we eval...

Descripción completa

Detalles Bibliográficos
Autores principales: Nava-Molina, Lesly, Uchida-Fuentes, Toyokazu, Ramos-Tovar, Héctor, Fregoso-Padilla, Martha, Rodríguez-Monroy, Marco Aurelio, Vega, Ana V., Navarrete-Vázquez, Gabriel, Andrade-Jorge, Erik, Villalobos-Molina, Rafael, Ortiz-Ortega, Ricardo, Vilches-Flores, Alonso
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7055595/
https://www.ncbi.nlm.nih.gov/pubmed/32132523
http://dx.doi.org/10.1038/s41387-020-0110-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7055595/
https://www.ncbi.nlm.nih.gov/pubmed/32132523
http://dx.doi.org/10.1038/s41387-020-0110-0

Ejemplares similares